Assessing new drugs and technologies in chronic disease patients using unpublished data sources
There is good evidence that trial reports in academic journals represent an incomplete picture of the data collected, and are an unsatisfactory source of information. Our recent Cochrane review highlighted the existence of unpublished data (which often contains negative data) for newer oral anticoagulant drugs, which has net been assessed, and there are reports of several side effects related to GLP-1 analogues and newer anti-obesity drugs that have not yet been reviewed. We are therefore planning a series of complex systematic reviews that include regulatory documents and Clinical study reports to evaluate new drugs and some technologies in widespread use where there is uncertainty about the benefit and harms profiles.
3.1 What are the benefits and harms of cholesterol lowering drugs to prevent CVD based on clinical study reports and summary of regulatory comments? (Stage 1 review)
3.2 Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation: a systematic review and meta-analysis incorporating unpublished clinical study reports.
Kamal R. Mahtani, Carl Heneghan, Igho Onakpoya, David Nunan, Nia Roberts, Beth Stuart.
3.3 What are the benefits and harms of Glucagon-like peptide-1 (GLP-1)  analogues in the summary of regulatory comments)
3.4 Benefits and harms of Mysimba® (naltrexone-bupropion) in the management of overweight and obesity: a systematic review and meta-analysis of unpublished clinical study reports
Onakpoya I , Spencer E, Stuart B, Aronson J, Mahtani K, Heneghan C
3.5 What is the role of genetics in primary care?
3.5.1 Genetic profiling to inform therapeutic decisions in primary care – a qualitative meta-synthesis of barriers and enablers
Ralph Akyea, Laura Condon, Nadeem Qureshi, Lorna Duncan, Rupert Payne, Kamal R. Mahtani, Joe Kai
3.5.2 Genetic profiling to inform therapeutic decisions in primary care – a systematic review of relevant drugs
Lorna Duncan, Rupert Payne, Sam Merriel, Ralph Akyea, Nadeem Qureshi, Kamal R. Mahtani, Nia Roberts
3.6 Using pedometers and accelerometers to increase physical activity and improve health in patients with diabetes, obesity and cardiovascular disease: a systematic review and meta-analysis
Alex Hodkinson, Maria Panagioti, Evangelos Kontopantelis, Peter Bower, Harm Van Marwijk, Charles Adeniji
Additional review outputs
3.7 Factors and variation driving inappropriate opioid analgesic prescribing in the community: a systematic review
Georgia Richards, Carl Heneghan, Kamal Mahtani, Ben Goldacre
Aronson JK, Heneghan C, Mahtani KR, Plüddemann A.
BMJ Evid Based Med. 2018 Jun 29. pii: bmjebm-2018-111025. doi: 10.1136/bmjebm-2018-111025.
Plüddemann A, Aronson JK, Onakpoya I, Heneghan C, Mahtani KR.
BMJ Evid Based Med. 2018 Jun 27. pii: bmjebm-2018-110990. doi: 10.1136/bmjebm-2018-110990.
Mahtani KR, Jefferson T, Heneghan C, Nunan D, Aronson JK.
BMJ Evid Based Med. 2018 Aug;23(4):127-130. doi: 10.1136/bmjebm-2018-110965. Epub 2018 May 19.
Heneghan C, Aronson JK, Goldacre B, Mahtani KR, Plüddemann A, Onakpoya I.
BMJ. 2017 Dec 7;359:j5515. doi: 10.1136/bmj.j5515.
Heneghan CJ, Goldacre B, Onakpoya I, Aronson JK, Jefferson T, Pluddemann A, Mahtani KR.
BMJ Open. 2017 Dec 6;7(12):e017125. doi: 10.1136/bmjopen-2017-017125
BMJ Opinion: Kamal R Mahtani, Tom Jefferson, and Carl Heneghan: What makes a systematic review “complex”? December 12, 2017